Document:

Exhibit 10.1

    

    
      

      

      

       

      SECOND AMENDED AND RESTATED

      STRATEGIC ADVISORY SERVICES AGREEMENT

      (“SUMMARY PAGE”)

      

      

      This Second Amended and Restated Strategic Advisory Services Agreement is entered into and made effective as of January 9, 2020, and amends and restates the Strategic
        Advisory Service Agreement dated January 15, 2018, as amended on March 22, 2019, by and between B. Lynne Parshall and Ionis Pharmaceuticals, Inc. (“Ionis”).

      

      

      	
              Date of Strategic Advisory Services Agreement: (“Agreement”)

            	 	
              January 15, 2018 (“Effective Date”).  Effective Date
                of Second Amendment and Restatement January 9, 2020.

            
	 	 	 
	
              Name of Strategic Advisor:

            	 	
              B. Lynne Parshall (hereinafter “Strategic Advisor”).

            
	 	 	 
	
              Scope of Strategic Advisory Services:

            	 	
              As set forth on Schedule A attached hereto.

            
	 	 	 
	
              Duration of Strategic Advisory Services (the “Strategic
                  Advisory Period”):

            	 	
              Until termination by Ionis or Strategic Advisor in accordance with Section 8 of Exhibit A below.

            
	 	 	 
	
              Consideration for Strategic Advisory Services:

            	 	
              As set forth on Schedule B attached hereto.

            
	 	 	 
	
              Time Provided by Strategic Advisor:

            	 	
              As set forth on Schedule A attached hereto.

            

      

      

      
        In addition to such compensation, Ionis will reimburse Strategic Advisor for Ionis approved travel and other out-of-pocket costs reasonably incurred in the course of
          performing Strategic Advisory Services under this Agreement as further described on Schedule B attached hereto.

         

        

      

      Strategic Advisor agrees to provide Ionis with Strategic Advisory Services on the terms described above and according to the additional terms attached hereto as
        Exhibit A.  In this Agreement references to Ionis, including but not limited to Sections 3-6 of Exhibit A, will include Ionis’ affiliate companies where applicable.

      

      

      	 	
              Strategic Advisor

            	 	
              Ionis Pharmaceuticals, Inc.

            
	
              By (Signature):

            	
              /s/ B. Lynne Parshall

            	 	
              /s/ Brett Monia

            
	 	 	 	 
	
              Date:

            	
              January 9, 2020

            	 	
              January 9, 2020

            
	
              Printed Name:

            	
              B. Lynne Parshall

            	 	
              Brett Monia

            

      

      

      Social Security or Employer Tax ID Number to be provided separately via W-9 form or foreign equivalent.

      

      

      
        1 of 8

        
          

      

      
      EXHIBIT A

      

      

      TERMS OF STRATEGIC ADVISORY AGREEMENT

      

      

      
        
          	1.	
                  Engagement of Services

                

        

      

      

      

      Strategic Advisor is retained to perform certain services, as needed and requested by Ionis, which services are specifically described on Schedule A attached hereto (“Strategic Advisory Services”).  Strategic Advisor will perform such Strategic Advisory Services to the best of Strategic Advisor’s talent and
        ability.

      

      

      
        
          	2.	
                  Compensation

                

        

      

      

      

      As full and complete compensation for Strategic Advisory Services and for the discharge of all of Strategic Advisor’s obligations hereunder, Ionis will pay Strategic
        Advisor at the rate set forth on Schedule B attached hereto. Strategic Advisor will invoice Ionis on a quarterly basis for Strategic Advisor fees and reimbursable expenses, and Ionis, upon its approval, will pay all undisputed fees and expenses
        within 30 days after Ionis’ receipt of the invoice.

      

      

      
        
          	3.	
                  Independent Contractor

                

        

      

      

      

      Strategic Advisor is an independent contractor and not an employee of Ionis.  Strategic Advisor has no authority to obligate Ionis by contract or otherwise.  Strategic
        Advisor will not be eligible for any employee benefits.  Taxes will be the sole responsibility of Strategic Advisor.

      

      

      
        
          	4.	
                  Additional Activities

                

        

      

      

      

      
        
          	(a)	
                  Strategic Advisor agrees that during the Strategic Advisory Period and for one year thereafter, Strategic Advisor will not attempt to induce any employee or employees of Ionis
                    to terminate their employment with, or otherwise cease their relationship with Ionis.

                

        

      

      

      

      
        
          	(b)	
                  Strategic Advisor acknowledges that Ionis has developed, through an extensive acquisition process, valuable information regarding actual or prospective partners, licensors,
                    licensees, clients, customers and accounts of Ionis (“Trade Secret Information”). Strategic Advisor acknowledges that Strategic
                    Advisor’s use of such Trade Secret Information after the termination of the Strategic Advisory Period would cause Ionis irreparable harm. Therefore, Strategic Advisor also agrees that Strategic Advisor will not utilize any Trade Secret
                    Information to solicit the business relationship or patronage of any of the actual or prospective partners, licensors, licensees, clients, customers or accounts of Ionis.

                

        

      

      

      

      
        
          	(c)	
                  The restrictions set forth in this Section 4 are considered by the parties to be reasonable for the purposes of protecting Ionis’ business.  However, if any such restriction is
                    found by a court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it will be interpreted to extend only over the
                    maximum period of time, range of activities or geographic areas as to which it may be enforceable.

                

           

          

        

      

      
        2 of 8

        
          

      

      
      
        
          	5.	
                  Confidential Information

                

        

      

      

      

      
        
          	(a)	
                  Ionis possesses confidential information that has been created, discovered, developed by, or otherwise become known to Ionis (including, without limitation, information
                    created, discovered, developed or made known by Strategic Advisor arising from the Strategic Advisory Services).

                

        

      

      

      

      
        
          	

                	(i)	
                  All such information is hereinafter referred to as “Confidential
                      Information.”  By way of illustration, but not limitation, Confidential Information includes:  (A) inventions, developments, designs, improvements, trade secrets, ideas, formulas, source and object codes, programs, other works
                    of authorship, organisms, plasmids, expression vectors, know-how, processes, cell lines, discoveries, techniques, data and documentation systems (hereinafter collectively referred to as “Inventions”); and (B) information regarding plans for research, development, new products, clinical data, pre-clinical product data, clinical trial patient data, marketing and
                    selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, as well as information regarding the skills and compensation of employees of Ionis.

                

        

      

      

      

      
        
          	

                	(ii)	
                  All Confidential Information will be the sole property of Ionis and its assigns, and Ionis and its assigns will be the sole owner of all patents, copyrights and other rights in
                    connection with such Confidential Information.  At all times, both during the term of this Agreement and for five years after its termination, Strategic Advisor will keep in confidence and trust all Confidential Information and will not
                    use, disclose, lecture upon or publish any Confidential Information or anything related to such information without Ionis’ prior written consent.  Any permitted disclosures will be made in strict compliance with the Ionis publication
                    and presentation clearance policy.

                

        

      

      

      

      
        
          	(b)	
                  Strategic Advisor also understands that Ionis has received and in the future, will receive valuable information from third parties that is confidential or proprietary (“Third-Party Information”) subject to a duty on the part of Ionis to maintain the confidentiality of such information and to use it
                    only for certain limited purposes.  During the term of this Agreement and for five years thereafter, Strategic Advisor will hold Third-Party Information in the strictest confidence and will not disclose or use Third-Party Information
                    except as permitted by the agreement between Ionis and such third party, unless expressly authorized to act otherwise by an officer of Ionis in writing.  Any permitted disclosures will be made in strict compliance with Ionis publication
                    and presentation clearance policy.

                

        

      

      

      

      
        
          	(c)	
                  The obligations of Section 5 will not apply to information that Strategic Advisor can establish by written records: (i) was known by Strategic Advisor prior to the receipt of
                    Confidential Information; (ii) was disclosed to Strategic Advisor by a third party having the right to do so; (iii) was, or subsequently became, in the public domain through no fault of Strategic Advisor, its officers, directors,
                    affiliates employees or agents; (iv) was independently developed by Strategic Advisor without use of Confidential Information; or (v) was disclosed by Strategic Advisor pursuant to any judicial, governmental or stock exchange request,
                    requirement or order, so long as Strategic Advisor provided Ionis with sufficient prior notice in order to allow Ionis to contest such request, requirement or order.

                

           

          

        

      

      
        3 of 8

        
          

      

      
      
        
          	6.	
                  Inventions

                

        

      

      

      

      In the course of performing Strategic Advisory Services for Ionis, Strategic Advisor may develop new ideas or Inventions or make other contributions of value to Ionis.

      

      

      
        
          	(a)	
                  Strategic Advisor hereby assigns to Ionis Strategic Advisor’s entire right, title and interest in and to any and all Inventions (and all patent rights, copyrights, and all
                    other rights in connection therewith, hereinafter referred to as “Proprietary Rights”) whether or not patentable or registrable
                    under patent, copyright or similar statutes, made or conceived of or reduced to practice or learned by Strategic Advisor, either alone or jointly with others, as a result of performing Strategic Advisory Services hereunder.  All
                    Inventions assigned to Ionis pursuant to this section will be known as “Company Inventions”.  Strategic Advisor agrees that all
                    Proprietary Rights and Company Inventions are Ionis’ sole property.  Strategic Advisor agrees, upon request, to execute, verify and deliver assignments of such Proprietary Rights to Ionis or its designee.  Strategic Advisor understands
                    that, to the extent this Agreement will be construed in accordance with the laws of any state which precludes a requirement in an agreement to assign certain classes of inventions made by an individual acting as a Strategic Advisor,
                    this section will be interpreted not to apply to any inventions that a court rules and/or Ionis agrees falls within such classes.

                

        

      

      

      

      
        
          	(b)	
                  Strategic Advisor further agrees to assist Ionis in every proper way to obtain, from time to time, and to enforce United States and foreign Proprietary Rights relating to
                    Company Inventions in any and all countries.  To that end Strategic Advisor will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Ionis may reasonably request for use in
                    applying for, obtaining, sustaining and enforcing such Proprietary Rights relating to Company Inventions.  Strategic Advisor’s obligation to assist Ionis in obtaining and enforcing Proprietary Rights relating to Company Inventions in
                    any and all countries will continue beyond the termination of this Agreement, but Ionis will compensate Strategic Advisor at a reasonable rate after such termination for the time actually spent by Strategic Advisor at Ionis’ request in
                    connection with such assistance.  If Ionis is unable, after reasonable effort, to secure Strategic Advisor’s signature on any document needed to apply for or prosecute any Proprietary Rights relating to a Company Invention, Strategic
                    Advisor hereby irrevocably designates and appoints Ionis and its duly authorized officers and agents as  her agent and attorney in fact, to act for and on Strategic Advisor’s behalf to execute, verify and file any such applications and
                    to do all other lawfully permitted acts to further the prosecution and issuance of any such Proprietary Rights with the same legal force and effect as if executed by Strategic Advisor.

                

           

          

        

      

      
        4 of 8

        
          

      

      
      
        
          	(d)	
                  During the term of this Agreement, Strategic Advisor will promptly disclose to Ionis, or any persons designated by it, fully and in writing and will hold in trust for the sole
                    right and benefit of Ionis any and all Company Inventions, whether or not patentable or protectable by copyright.  At the time of each such disclosure, Strategic Advisor will advise Ionis in writing of any Inventions that Strategic
                    Advisor believes are not subject to the assignment provisions of Section 6(a) above, and Strategic Advisor will at that time provide to Ionis in writing all evidence necessary to substantiate that belief.  Strategic Advisor will not be
                    obligated to disclose information received by Strategic Advisor from others under a contract of confidentiality.  In addition, after termination of this Agreement, Strategic Advisor will disclose to Ionis all patent applications filed
                    by Strategic Advisor relating to any Company Inventions or relating to any work performed by Strategic Advisor on behalf of Ionis.

                

        

      

      

      

      
        
          	7.	
                  Previous Strategic Advisory Relationships

                

        

      

      

      

      Strategic Advisor represents that Strategic Advisor’s performance of Strategic Advisory Services, as well as Strategic Advisor’s performance of the rest of Strategic
        Advisor’s obligations under the terms of this Agreement, will not breach any agreement to keep in confidence any proprietary information acquired by Strategic Advisor in confidence or in trust from another entity prior to the date of this
        Agreement.  Strategic Advisor agrees not to bring to Ionis or to use in the performance of Strategic Advisory Services for Ionis any materials or documents of a present or former employer or client of Strategic Advisor, or any materials or
        documents obtained by Strategic Advisor under a confidentiality agreement imposed by reason of another of Strategic Advisor’s Strategic Advisory relationships, unless such materials or documents are generally available to the public or Strategic
        Advisor has authorization from such present or former employer or client for the possession and unrestricted use of such materials.

      

      

      
        
          	8.	
                  Termination; Survival

                

        

      

      

      

      (a)         The term of this Agreement will begin on January 15, 2018 and will end
          when terminated by either Ionis or Strategic Advisor.  Ionis may terminate this Agreement at any time for any reason by providing Strategic Advisor at least 120 days advance written notice.  Strategic Advisor may terminate this Agreement at any
          time for any reason by providing Ionis at least 120 days advance written notice; provided, once Strategic Advisor delivers such a termination notice, Ionis
          may elect to accelerate the effective date of such termination.  Upon any termination, Ionis will pay Strategic Advisor for any Strategic Advisory Services appropriately rendered and for any out of pocket expenses reasonably incurred on behalf of
          Ionis, up to and including the termination date.

      

      

      (b)          Sections 9 and 10, the last sentence of the paragraph of Schedule B
          entitled “Ionis Stock Awards” and the last paragraph of Schedule B will survive termination of this Agreement.  In addition, upon expiration or termination of this Agreement, each party will be released from all obligations and liabilities to the
          other occurring or arising after the date of such expiration or termination, except that any termination or expiration of this Agreement will not relieve Strategic Advisor of Strategic Advisor’s obligations under Sections 4, 5, 6, 7, 9, 10 and 11
          hereof, nor will any such expiration or termination relieve Strategic Advisor or Ionis from any liability arising from any breach of this Agreement.  Upon expiration or termination of this Agreement for any reason whatsoever, Strategic Advisor
          will promptly surrender and deliver to Ionis any and all notes, business records, memoranda, specifications, devices, formulas, molecules, cells, storage media, including calculations, sequences, data and other materials of any nature pertaining
          to Strategic Advisory Services for Ionis, as well as any documents or data of any description (or any reproduction of any documents or data) containing or pertaining to any Trade Secret Information, Ionis’ Confidential Information or Third Party
          Information.

          

        

      
        5 of 8

        
          

      

      
      
        
          	9.	
                  Arbitration

                

        

      

      

      

      
        
          	(a)	
                  Ionis and Strategic Advisor agree to resolve by arbitration all disputes, claims or controversies (“Claims”), past, present or future, whether or not arising out of this Agreement or its termination, that Ionis may have against Strategic Advisor or that Strategic Advisor may have against any of the
                    following (i) Ionis; (ii) Ionis officers, directors; employees or agents; (iii) Ionis’ subsidiary or affiliated entities, joint ventures, or joint employers; (iv) Ionis’ benefit plans or the plans’ sponsors, fiduciaries, administrators,
                    affiliates and agents; and/or (v) all successors and assigns of any of the foregoing.  The Claims covered by this Agreement include all disputes that Ionis or Strategic Advisor could otherwise pursue in state or federal court including,
                    but not limited to, Claims based on any state, federal, or local statute, regulation or ordinance (including Claims for discrimination, retaliation, harassment, unpaid wages or violation of state or federal wage and hour laws), as well
                    as common law Claims (including Claims for breach of contract, breach of the implied covenant of good faith and fair dealing, wrongful discharge, defamation, misrepresentation, fraud, or infliction of emotional distress).  Ionis and
                    Strategic Advisor anticipates that this Section 9 provides the benefits of a speedy, less formal, impartial, final and binding dispute resolution procedure.

                

        

      

      

      

      
        
          	(b)	
                  To the maximum extent permitted by law, Strategic Advisor hereby waives any right to bring on behalf of persons other than Strategic Advisor, or to otherwise participate with
                    other persons in, any class, collective or representative action (i.e. a type of lawsuit in which one or several persons sue on behalf of a larger group of persons).

                

        

      

      

      

      
        
          	(c)	
                  The arbitration will be conducted by a single neutral arbitrator in accordance with the then-current Commercial Arbitration and Mediation Procedures of the American Arbitration
                    Association (“AAA”).  The arbitration will take place in San Diego, California.  Ionis will pay the arbitrator’s fee and will
                    bear all administrative charges by AAA.  All parties will be entitled to engage in reasonable pre-hearing discovery to obtain information to prosecute or defend the asserted claims.  Any disputes between the parties regarding the nature
                    or scope of discovery will be decided by the arbitrator.  The arbitrator will hear and issue a written ruling upon any dispositive motions brought by either party, including but not limited to, motions for summary judgment or summary
                    adjudication of issues.  After the hearing, the arbitrator will issue a written decision setting forth the award, if any, and explaining the basis therefore.  The arbitrator will have the power to award any type of relief that would be
                    available in court.  The arbitrator’s award will be final and binding upon the parties and may be entered as a judgment in any court of competent jurisdiction.  If there is conflict in the arbitration procedures set forth in this
                    Agreement and the AAA rules specified above, the AAA rules will control.  Notwithstanding the foregoing, and regardless of what is provided by the AAA rules, the arbitrator will not have authority or jurisdiction to consolidate claims
                    of different individuals or entities into one proceeding, nor will the arbitrator have authority or jurisdiction to hear the arbitration as a class action.  As noted above, Strategic Advisor has agreed to waive any right to bring any
                    class, collective or representative action.  To the extent that the class, collective or representative action waiver described above is not enforceable, the issue of whether to certify any alleged or putative class for a class action
                    proceeding must be decided by a court of competent jurisdiction.  The arbitrator will not have authority or jurisdiction to decide class certification, collective or representative action issues.  Until any class certification,
                    collective, or representative action issues are decided by the court, all arbitration proceedings will be stayed, and the arbitrator will take no action with respect to the matter.  However, once any issues regarding class
                    certification, collective, or representative action have been decided by the court, the arbitrator will have authority to decide the substantive claims.

                

           

          

        

      

      
        6 of 8

        
          

      

      
      
        
          	10.	
                  Indemnification

                

        

      

      

      

      
        
          	(a)	
                  Ionis will indemnify, defend and hold Strategic Advisor harmless against any and all losses, costs, expenses and damages (including reasonable attorney’s fees) (“Loss(es)”)
                    incurred as a result of any third party claims, suits, actions, demands or proceedings resulting or arising  from the performance of Strategic Advisory Services as specifically directed by Ionis in accordance with the Agreement to the
                    extent such Loss(es) are not the result of Strategic Advisor’s gross negligence, intentional misconduct or material breach of this Agreement.

                

        

      

      

      

      
        
          	(b)	
                  Ionis’ agreement to indemnify, defend and hold  Strategic Advisor harmless is conditioned upon the Strategic Advisor (i) providing written notice to Ionis of any claim, demand
                    or action arising out of the indemnified activities within thirty (30) days after Strategic Advisor has knowledge of such claim, demand or action, provided
                    that the failure to so notify Ionis shall not relieve Ionis of its obligations hereunder except to the extent such failure shall have actually materially prejudiced Ionis; (ii) permitting Ionis to assume full responsibility to
                    investigate, prepare for and defend against any such claim or demand; (iii) assisting Ionis, at Ionis’ reasonable expense, in the investigation of, preparation of and defense of any such claim or demand; (iv) undertaking reasonable
                    steps to mitigate any loss, damage or expense with respect to the applicable claim or demand; and (v) not settling such claim or demand without Ionis’ prior written consent.

                

        

      

      

      

      
        
          	(c)	
                  Ionis will endeavor to include Strategic Advisor as a covered attorney on its insurance policy for attorneys who advise Ionis.

                

           

          

        

      

      
        7 of 8

        
          

      

      
      
        
          	11.	
                  Miscellaneous

                

        

      

      

      

      
        
          	(a)	
                  The rights and liabilities of the parties hereto will bind and inure to the benefit of their respective successors, heirs, executors and administrators, as the case may be; provided that, as Ionis has specifically contracted for Strategic Advisor’s services, Strategic Advisor may not assign or delegate Strategic Advisor’s
                    obligations under this Agreement either in whole or in part without Ionis’ prior written consent.

                

        

      

      

      

      
        
          	(b)	
                  Because Strategic Advisor’s services are personal and unique and because Strategic Advisor has access to and become acquainted with Ionis’ Confidential Information, the parties
                    agree that in the event of a threatened or actual material breach of this Agreement by Strategic Advisor injunctive relief would be appropriate.  As such, Ionis has the right to enforce this Agreement and any of its provisions by
                    injunction, specific performance or other equitable relief without prejudice to any other rights and remedies that Ionis may have for a breach of this Agreement.

                

        

      

      

      

      
        
          	(c)	
                  This Agreement will be governed by and construed according to the laws of the State of California as such laws are applied to contracts entered into and performed entirely
                    within such State.  If any provision of this Agreement is held to be or becomes invalid, illegal or unenforceable, such provision will be validly reformed to approximate as nearly as possible the intent of the parties and the remainder
                    of this Agreement will not be affected thereby and will remain valid and enforceable to the greatest extent permitted by law.

                

        

      

      

      

      
        
          	(d)	
                  This Agreement, and all other documents mentioned herein, constitute the final, exclusive and complete understanding and agreement of the parties hereto and supersedes all
                    prior understandings and agreements.  Any waiver, modification or amendment of any provision of this Agreement will be effective only if in writing and signed by the parties hereto.

                

        

      

      

      

      
        
          	(e)	
                  Any notices required or permitted hereunder will be given to the appropriate party at the address specified on the Summary Page or at such other address as the party will
                    specify in writing.  Such notice will be deemed given upon personal delivery to the appropriate address, or by facsimile transmission (receipt verified and with confirmation copy followed by another permitted method), sent by express
                    courier service, or, if sent by certified or registered mail, three (3) days after the date of mailing.

                

           

          

        

      

      
        8 of 8

        
          

      

      
      SCHEDULE  A

      

      

      Strategic Advisory Services

      

      

      Ionis Board of Directors

      You will serve on the Ionis board of directors as a nonemployee director until your resignation or removal in accordance with Ionis’ corporate charter.  You will serve on
        the Agenda committee of the Board, and Ionis will periodically evaluate your ability to serve on other Board committees to the extent permitted by applicable SEC and Nasdaq rules. You will participate in other Board Committee meetings as requested
        as a non-member.

      

      

      Akcea

      Your services to Akcea will be handled by a separate agreement between you and Akcea.  Any services you provide Akcea will not count towards hours worked under this
        Agreement.

      

      

      Strategic Neurology/Rare Disease Subsidiary Board of Directors

      When Ionis forms a strategic neurological/rare disease focused  subsidiary, you will serve on the board of directors of such subsidiary as a non employee director on the
        same terms as other non employee directors until your resignation or removal in accordance with the subsidiary’s corporate charter.

      

      

      Additional Strategic Advisory Services

      

      

      You will provide Ionis strategic advice regarding Ionis’ business, including but not limited to the following:

      

      

      For calendar year 2020, you will provide approximately seventy-three full days of strategic advice.  For each year following 2020, you and Ionis will mutually agree on
        the approximate number of business days each month you will provide strategic advice during such year.  You will make yourself generally available for conference calls and in person meetings Ionis invites you to attend.  You will travel to
        locations as reasonably requested by Ionis, including to Ionis, Akcea, Ionis’ partners, or other locations where Ionis is conducting corporate development activities (e.g. JP Morgan conference or strategic off-site meetings).  You and Ionis expect
        that, you will participate in Ionis’ development management committee (DMC) meetings, Ionis’ affiliate’s and Biogen joint steering committee meetings, and when requested, Ionis’ strategic management meetings.  As requested by Ionis, you will
        facilitate Ionis’ strategic partnerships and help develop Ionis’ subsidiaries’ and affiliates’ senior management teams.  You will work with the Executive Chairman, CEO and others on strategic planning and direction for the Company.  You will
        participate in major corporate communication initiatives, including business/financial messaging.  You will participate in structuring and negotiating as requested new strategic alliances.  Your advisory services may include providing Ionis legal
        advice.

      

      

      You and Ionis will reasonably coordinate to have you present on site for board of directors meetings, and a few days before and/or after such meetings to perform
        strategic advisory services.  The time you spend preparing for or attending board of directors or board committee meetings for Ionis or any subsidiary will not count towards your commitment to perform additional strategic advisory services outlined
        above.

      

      

      While you are providing such services, Ionis will make an appropriate level of administrative and technical personnel available to facilitate your performance of Advisory
        Services at no cost to you, including, without limitation IT support and access to Ionis’ electronic calendar and IT systems that are necessary to perform your duties.

      
         

        

      

      
        
          	
                  Schedule A

                	
                  Page 1

                

        

        
          

      

      SCHEDULE  B

      

      

      Compensation for Strategic Advisory Services

      

      

      Ionis Board of Directors

      For your service on the Ionis board of directors, you will receive the same compensation as Ionis provides its other nonemployee directors.  You will receive the same
        annual equity awards as Ionis’ other nonemployee directors.  You will also be eligible for any benefits (including any applicable health benefits) Ionis provides to its nonemployee directors.

      

      

      Strategic Neurology/Rare Disease Subsidiary Board of Directors

      For your service on the board of directors of Ionis’ strategic neurological/rare disease subsidiary (if formed), you will receive the same compensation (including equity
        awards) as such subsidiary provides its other nonemployee /outside directors.

      

      

      Additional Strategic Advisory Services

      For your other strategic advisory services, starting in the fiscal year ending in 2020, Ionis will pay you as follows:

      
        
          	

                	•	
                  $300,000 for services rendered through December 31, 2020 to be paid in equal quarterly installments; provided, however, that if you provide more than seventy-three full days of service during the aforementioned period, then payment for days above seventy-three will be $5,000 per day to be paid at the end of 2020.

                

        

      

      
        
          	

                	•	
                  You will not be eligible for an Ionis performance bonus.

                

        

      

      
        
          	

                	•	
                  Ionis will evaluate its needs and your availability at the end of 2020.

                

        

      

      

      

      Ionis Stock Awards

      Since you transitioned seamlessly from an Ionis employee to a nonemployee director, the stock options and RSUs you received for your previous service as an Ionis employee
        will continue to vest so long as your Continuous Service (as defined in the applicable equity plan) continues.  Once you are no longer serving on the Ionis board and no longer providing strategic advisory services, to the extent permitted by the
        terms of the applicable stock option agreement, your vested stock options will not terminate until the earlier of 18 months following your retirement or the expiration of the original term of such stock option.

      

      

      For Ionis-directed travel and lodging Ionis will reimburse you for such travel, lodging and related expenses or reasonable rate equivalents for lodging, car and meals you
        provide.  All such reimbursements will be in accordance with Ionis’ travel policy and you will provide Ionis reasonably acceptable supporting documentation.

      

      

      For the 18 months following the end of your Ionis board of directors services, if you are eligible for continued health coverage under COBRA, Ionis will pay your COBRA
        premium payments sufficient to continue your coverage at your then current level, or if COBRA is not available, Ionis will pay you an amount equal to the cost of comparable replacement coverage.

       

      

       

      

      
        
          	
                  Schedule B

                  

                	
                  Page 1Exhibit 10.1

 

 

  

January 9, 2020

 

Maged Shenouda

149 Bedford Avenue

Brooklyn, NY 11211

 

Dear Mr. Shenouda:

 

On behalf of Relmada Therapeutics, Inc:
(the "Company"), I am pleased to offer you the position of Chief Financial Officer. Speaking for myself, as well as the
other members of the Board of Directors, we are all impressed with your credentials and look forward to your future success in
this position. The terms of your employment are set herein ("Employment Letter").

 

1. Position.
The terms of your position with the Company are as set forth below:

 

(a) You
shall serve as Chief Financial Officer of the Company with such responsibilities duties and authority as are assigned to you by
the Chief Executive Officer (CEO). You shall report directly to the CEO. You shall perform your duties for the Company at the Company’s
offices, except as otherwise agreed with the CEO and for travel that may be necessary or appropriate in connection with the performance
of your duties hereunder. The headquarters of the Company is located in New York City.

 

(b) You
shall faithfully devote his full business/working time, attention and energy to the business and affairs of the Company and the
performance of his duties, which may be modified periodically by the CEO and to use his best efforts to perform such responsibilities
faithfully and efficiently. Without limiting the generality of the foregoing paragraph, the employee may join professional associations
and otherwise be involved with any other business activities, to the extent that, in the reasonable judgment of the CEO, such other
business pursuits and activities do not (i) interfere in any material respect with your ability to discharge Employee's duties
and responsibilities to the Company, whether or not such activity is pursued for gain, profit or other pecuniary advantage, or
(ii) violate the Conflicts provision of Employee's Non-Disclosure Agreement.

 

2. 
Effective Date. The effective date of this agreement shall be January 8, 2020 (the “Effective Date”).

 

3. 
Proof of Right to Work. For purposes of federal immigration law, you will be required to provide to the Company documentary
evidence of your identity and eligibility for employment in the United States.

   

4. 
Compensation.

 

(a) Base
Salary. You will be paid an annual base salary of Three Hundred Ninety Five Thousand dollars ($395,000), which will be paid
in accordance with the Company’s regular payroll practices. You will also be paid a sign-on bonus of $25,000.

 

(b) Performance
Cash Bonus. You shall be entitled to participate in a bonus program, which shall be established by the Board pursuant to which
the Board shall award bonuses to you, based upon the achievement of written individual and corporate objectives such as the CEO
or Board shall determine. Upon the attainment of such performance objectives, in addition to your base salary, you shall be entitled
to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of your base salary.

 

     

     

    

  

(c) Stock
Option and Restricted Stock Grants. During the Term of this Agreement, you may also be awarded grants under the Company’s
2014 Stock Option and Equity Incentive Plan, as amended (the “Stock Plan”), subject to Board approval. For the avoidance
of doubt, your options granted to you as a Director of the Company shall continue to vest in accordance with the terms of the Stock
Plan, so long as you remain employed by the Company.

 

5. 
Benefits.

 

(a) Benefit
Plan — Health Insurance, Retirement and Stock Option Plan. The Company will provide you with the opportunity to participate
in the standard benefits plans currently available to other similarly situated employees. The Company reserves the right to cancel
and/or change the benefits plans it offers to its employees at any time, subject to applicable law.

 

(b) Vacation;
Sick Leave. You will be entitled to 20 days paid vacation per year, pro-rated for the remainder of this calendar year and pro-rated
by the number of hours worked. Vacation may not be taken before it is accrued. You will be entitled to 5 days paid sick leave per
year pro-rated.

 

(c) Other
Benefits. The Company will provide you with standard business reimbursements (including mileage, supplies, long distance calls),
subject to Company policies and procedures and with appropriate receipts. In addition, you will receive any other statutory benefits
required by law.

 

(d) Reimbursement
of Expenses. You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably
incurred by you on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement
policies in effect from time to time.

 

6.  Confidential
Information and Invention Assignment Agreement. You have executed the Company’s Confidential Information and Invention
Assignment Agreement, which remains in full force and effect.

 

7. 
At-Will Employment. Your. employment with the Company will be on an "at will" basis meaning that either
you or the Company may terminate your employment at any time for any reason or no reason, upon written notification to the other
party, without further obligation or liability, except as provided herein. In the event that your employment is terminated because
of your death or Disability, the Company’s only obligation to you shall be to pay earned, but unpaid, base salary (as of
the date of termination) and provide you, if eligible, with the option to elect health coverage under the Consolidated Omnibus
Budget Reconciliation Act of 1985, as amended (“COBRA”); provided that upon termination of your employment hereunder
due to death, your estate also shall be entitled to receive a single lump sum payment equal to three (3) months of your base salary,
payable within 30 days of your death. Upon termination of your employment for Cause (as defined below) you shall be paid any accrued
and unpaid base salary and benefits through the date of termination and shall have no further rights to any compensation or any
other benefits under the Agreement or otherwise.

 

(a) Termination
of Employment Other Than for Cause or Resignation for Good Reason (Not in Connection with a Change in Control). If the Company
terminates your employment other than for Cause or if you resign for Good Reason, in any case in circumstances other than those
described in Section 7(b), you shall be entitled to the following:

 

(i)  Subject
to Section 8 hereof, a single lump sum payment equal to six (6) months of your compensation (at the rate in effect as of the date
of termination), payable in accordance with the Company’s regular payroll practices in effect at the date of termination,
on the first payroll date following the date the Release (as defined in Section 8 hereof) becomes effective and irrevocable in
accordance with its terms.

 

    2

     

    

 

(ii)  Subject
to Section 8 hereof, continued health benefits for the 6-month period beginning on the date of termination, with such period to
run concurrently with any period for which you are eligible to elect health coverage under COBRA. Notwithstanding the foregoing,
you shall be required to pay any and all employee premiums associated with continued health benefits and, if you become employed
by another employer and become covered by such employer’s health benefits plan or program, the continued health benefits
and cash payments provided hereunder shall cease.

 

(iii) All
outstanding equity awards granted to you under the Company’s equity compensation plans shall become immediately vested and
exercisable (as applicable) as of the date of such termination and the performance goals with respect to such outstanding performance
awards, if any, will deemed satisfied at “target”.

 

(b) Change
in Control. If the Company terminates your employment other than for Cause or if you resign for Good Reason, in any case during
the 12-month period beginning on the date of a Change in Control (as defined in the 2014 Stock Option and Equity Incentive Plan,
as amended), you shall be entitled to the following:

 

(i) Subject
to Section 8 hereof, a single lump sum payment equal to six (6) months of your compensation (at the rate in effect as of the date
of termination), payable in accordance with the Company’s regular payroll practices in effect at the date of termination,
on the first payroll date following the date the Release (as defined in Section 8 hereof) becomes effective and irrevocable in
accordance with its terms.

 

(ii) Subject
to Section 8 hereof, continued health benefits for the 6-month period beginning on the date of termination, with such period to
run concurrently with any period for which you are eligible to elect health coverage under COBRA. Notwithstanding the foregoing,
you shall be required to pay any and all employee premiums associated with continued health benefits and, if you become employed
by another employer and become covered by such employer’s health benefits plan or program, the continued health benefits
and cash payments provided hereunder shall cease.

 

(iii) All
outstanding equity awards granted to you under the Company’s equity compensation plans shall become immediately vested and
exercisable (as applicable) as of the date of such termination and the performance goals with respect to such outstanding performance
awards, if any, will deemed satisfied at “target”.

  

(c) “Cause”
means: that the Company has elected to terminate your employment with the Company because a majority of the members of the Company’s
Board of Directors (the “Board”) has reasonably determined in good faith (after allowing you the opportunity to address
the alleged wrongdoing with the Board at a duly called meeting of the Board) that you have done any of the following: (i) failure
by you to perform your duties and responsibilities to the Company (or a Successor Company) or gross negligence or gross incompetence
in the performance of your duties, after written notice thereof and a failure to remedy such failure, if remediable, within sixty
(60) days of such notice; (ii) commission by you of any act of fraud, embezzlement, dishonesty or any other misconduct that has
caused or is reasonably expected to cause material injury to the Company (or a Successor Company, if appropriate), including commission
of conduct constituting a felony or crime involving fraud, moral turpitude or dishonesty; (iii) unauthorized use or disclosure
by you of any confidential information of the Company (or a Successor Company, if appropriate) or of any other party to whom you
owe an obligation of nonuse and nondisclosure as a result of your relationship with the Company (or a Successor Company, if appropriate);
(iv) if determined after an impartial investigation that you engaging in conduct prohibited by the Company (or Successor company,
if appropriate) policy governing harassment and discrimination; (v) material breach by you of any of your obligations under any
written agreement with the Company (or a Successor Company, if appropriate) after written notice thereof and a failure to remedy
such breach, if remediable, within sixty (60) days of such notice; or (vi) breach of fiduciary duty. “Successor Company”
means the successor entity resulting from a Change of Control or a parent or subsidiary of such successor entity.

 

    3

     

    

 

(d) “Good
Reason” means: (i) the Company’s material breach of any of its obligations under this Agreement; (ii) a material
reduction by the Company of your base salary or target bonus opportunity; (iii) a material change to the title, scope of your work
or employment duties; (iv) a material adverse change in reporting relationship; (v) an abandonment of, or fundamental change in,
the primary business or primary products of the Company, or (vi) the Company’s regular requirement that you perform services
in or relocate to a location that is more than fifty (50) miles from New York City. A termination of employment will not be deemed
to be for Good Reason unless the Company does not cure within 30 days after receipt of written notice from you specifying the Good
Reason and referring to your right to resign for Good Reason. Any resignation for Good Reason will be effective immediately upon
your giving notice of your resignation for Good Reason to the Company, conditioned upon your having provided proper notice of Good
Reason and time to cure in accordance with this provision.

 

(e) “Disability”
shall mean that you are unable due to a physical or mental condition to perform the essential functions of his position with or
without reasonable accommodation for ninety (90) consecutive days or for one-hundred and eighty (180) days in the aggregate during
any twelve (12) month period or based on the written certification by a licensed physician of the likely continuation of such condition
for either such period. 

 

(f) Mitigation.
In the event that you are entitled to severance pursuant to this Agreement, you have no duty to mitigate and your severance will
not be reduced for any reason.

 

8. Release.
Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to provide any severance payment
or benefit under Sections 7(a)(i), 7(a)(ii), 7(b)(i) or 7(b)(ii) hereof unless: (a) you or your legal representative first executes
within 45 calendar days after the date of presentment, a release of claims agreement in the form as to be provided by the Company
(the “Release”) and substantially similar to the form of Release attached hereto as Exhibit A, (b) you
do not revoke the Release, and (c) the Release becomes effective and irrevocable in accordance with its terms. The Company shall
provide the Release to you for your review within ten (10) days of the date of termination.

  

9.  Non-Solicitation.
You agree that during the term of your employment with the Company, and for a period of 24 months following the cessation of employment
with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of
the Company’s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing,
either for yourself or any other person or entity. For a period of 24 months following cessation of employment with the Company
for any reason or no reason, you shall not attempt to negatively influence any of the Company’s clients or customers from
purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person
either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution
or other entity in competition with the business of the Company.

 

10. Arbitration.
Any dispute or claim arising out of or in connection with your employment with the Company (except with regard to enforcement
of the Confidentiality Agreement) will be finally settled by arbitration in New York, New York in accordance with the
Commercial Arbitration Rules of the American Arbitration Association by one arbitrator appointed in accordance with said
rules. Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties
agree that this Agreement evidences a transaction involving interstate commerce and that the operation, interpretation and
enforcement of this arbitration provision, the procedures to be used in conducting an arbitration pursuant to this
arbitration provision, and the confirmation of any award issued to either party by reason of such arbitration, is governed
exclusively by the Federal Arbitration Act, 9 U.S.C. § 21 et seq. Notwithstanding the foregoing, the
parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel
arbitration in accordance with this paragraph, without breach of this arbitration provision. The Company shall pay all fees
and expenses for the arbitration itself, including the cost of the arbitrator. Each party shall pay its own legal fees and
costs in any legal proceedings.

 

    4

     

    

 

11. Indemnification.
On August 5, 2015, you have entered into an Indemnification Agreement with the Company which remains in full force and effect.

   

12. Section
280G. In the event it shall be determined that any payment or distribution by the Company to or for your benefit (whether paid
or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (the “Total Payments”),
is or will be subject to the excise tax (the “Excise Tax”) imposed by Section 4999 of the Internal Revenue Code
of 1986, as amended (the “Code”), then the Total Payments shall be reduced to the maximum amount that could
be paid to you without giving rise to the Excise Tax (the “Safe Harbor Cap”), if the net after-tax benefit to
you after reducing your Total Payments to the Safe Harbor Cap is greater than the net after-tax (including the Excise Tax) benefit
to you without such reduction. The reduction of the amounts payable hereunder, if applicable, shall be made by reducing such payment
that trigger the Excise Tax in the following order: (i) reduction of cash payments, (ii) cancellation of accelerated vesting of
performance-based equity awards (based on the reverse order of the date of grant), (iii) cancellation of accelerated vesting of
other equity awards (based on the reverse order of the date of grant), and (iv) reduction of any other payments due to you (with
benefits or payments in any group having different payment terms being reduced on a pro-rata basis). All mathematical determinations,
and all determinations as to whether any of the Total Payments are “parachute payments” (within the meaning of Section
280G of the Code), that are required to be made under this paragraph, including determinations as to whether the Total Payments
to you shall be reduced to the Safe Harbor Cap and the assumptions to be utilized in arriving at such determinations, shall be
made at the Company’s expense by the Company’s then current independent auditors, or such other nationally recognized
accounting firm selected by the Committee prior to the relevant change in control transaction.

 

13. Section
409A.

 

(a) In
General. It is the Company’s intent that this Agreement be exempt from the application of, or otherwise comply with,
the requirements of Section 409A of the Code (“Section 409A”). Specifically, any taxable benefits or payments
provided under this Agreement are intended to be separate payments that qualify for the “short-term deferral” exception
to Section 409A to the maximum extent possible, and to the extent they do not so qualify, are intended to qualify for the involuntary
separation pay exceptions to Section 409A, to the maximum extent possible. If neither of these exceptions applies, and if you are
a “specified employee” within the meaning of Section 409A, then notwithstanding any provision in this Agreement to
the contrary and to the extent required to comply with Section 409A, all amounts that would otherwise be paid or provided to you
during the first six (6) months following your date of termination shall instead be accumulated through and paid or provided (without
interest) on the first business day following the six-month anniversary of the date of termination. If the period during which
the Release must become effective and irrevocable in accordance with its terms spans two calendar years, then, to the extent required
to comply with Section 409A, any payment to be made under this Agreement will commence on the first payroll date that occurs in
the second calendar year and after the Release has become effective and irrevocable in accordance with its terms. Further, to the
extent required to comply with Section 409A: (i) the amount of any expense reimbursement to which you may be entitled hereunder
during a calendar year will not affect the amount of reimbursements to be provided in any other calendar year; (ii) your right
to receive reimbursement of an eligible expense hereunder is not subject to liquidation or exchange for another benefit; and (iii)
provided that the requisite documentation is submitted, the Company will reimburse your eligible expenses on or before the last
day of the calendar year following the calendar year in which the expense was incurred.

 

    5

     

    

  

(b) Separation
from Service. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement
providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment unless
such termination is also a “separation from service” within the meaning of Section 409A and the Participant is no longer
providing services (at a level that would preclude the occurrence of a “separation from service” within the meaning
of Section 409A) to the Company or its Affiliates as an employee or consultant, and for purposes of any such provision of this
Plan, references to a “termination,” “termination of employment” or like terms shall mean “separation
from service” within the meaning of Section 409A.

 

14. Assistance
in Litigation. Employee shall, during and after termination of employment, upon reasonable notice, furnish such information
and proper assistance to the Company as may reasonably be required by the Company in connection with any litigation in which it
or any of its subsidiaries or affiliates is, or may become a party; provided, however, that such assistance following termination
shall be furnished at mutually agreeable times and for mutually agreeable compensation.

 

15. Miscellaneous.
This Agreement, together with the Confidentiality Agreement, and Indemnification Agreement sets forth the terms of your employment
with the Company and supersedes any prior representations or agreements, whether written or oral. This Agreement may not be modified
or amended except by a written agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement
will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is
held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity,
illegality or unenforceability will be lessened or reduced to the extent possible or will be severed and will not affect any other
provision and this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable
provision had never been contained herein. This Agreement will be governed by New York law without reference to rules of conflicts
of law. All notices, requests, demands and other communications called for hereunder shall be in writing and shall be deemed given
(i) on the date of delivery if delivered personally, (ii) one (1) day after being sent by a well established commercial
overnight service, (iii) three (3) days after being mailed by registered or certified mail, return receipt requested,
prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses as the parties
may later designate in writing, (iv) upon confirmation of facsimile transfer, if sent by facsimile or (v) upon confirmation
of delivery when directed to the electronic mail address set forth below, if sent by electronic mail:

 

	 	If to the Company:	880 Third Avenue, 12th Floor
	 	 	New York, NY  10022

  

	 	If to you:	
        149 Bedford Avenue

        Brooklyn, NY 11211

 

16. Withholding
of Taxes. The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as
the Company is required to withhold pursuant to any law or government regulation or ruling.

 

    6

     

    

 

To indicate your acceptance
of this Agreement, please sign and date this letter in the space provided below and return it to me.

 

	Very truly yours,	 	ACCEPTED AND AGREED:
	 	 	 
	RELMADA THERAPEUTICS, INC.	 	MAGED SHENOUDA
	 	 	 
	By:	/s/ Sergio Traversa   	 	/s/ Maged Shenouda     
	 	Sergio Traversa

Chief Executive Officer	 	 
	 	 	 	 
	Date:  January 9, 2020	 	Date:  January 9, 2020

 

    7

     

    

  

EXHIBIT A

 

RELEASE OF CLAIMS

 

FOR AND IN CONSIDERATION
OF the payments and benefits (the “Separation Benefits”) to be provided to me in connection with the separation
of my relationship with the Company, in accordance with the Agreement between Relmada Therapeutics, Inc. (the “Company”)
and me dated as August 5, 2015 (the “Agreement”), which Separation Benefits are conditioned on my signing this
Release of Claims (“Release”) and which I will forfeit unless I execute and do not revoke this Release of Claims,
I, on my own behalf and on behalf of my heirs and estate, voluntarily, knowingly and willingly release and forever discharge the
Company, its subsidiaries, affiliates, parents, and stockholders, together with each of those entities’ respective officers,
directors, stockholders, employees, agents, fiduciaries and administrators (collectively, the “Releasees”) from
any and all claims and rights of any nature whatsoever which I now have against them up to the date I execute this Release, whether
known or unknown, suspected or unsuspected. This Release includes, but is not limited to, any rights or claims relating in any
way to my employment or consulting relationship with the Company or any of the other Releasees or the termination thereof, any
contract claims (express or implied, written or oral), including, but not limited to, the Agreement, or any rights or claims under
any statute, including, without limitation, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the
Older Workers’ Benefit Protection Act, the Rehabilitation Act of 1973 (including Section 504 thereof), Title VII of the 1964
Civil Rights Act, the Civil Rights Act of 1866 (42 U.S.C. § 1981), the Civil Rights Act of 1991, the Equal Pay Act, the National
Labor Relations Act, the Worker Adjustment and Retraining Notification Act, the Family Medical Leave Act, the Lilly Ledbetter Fair
Pay Act, the Genetic Information Non-Discrimination Act, the New York State Human Rights Law, the New York City Human Rights Law,
and the Employee Retirement Income Security Act of 1974, all as amended, and any other federal, state or local law. This Release
specifically includes, but is not limited to, any claims based upon the right to the payment of wages, incentive and performance
compensation, bonuses, equity grants, vacation, pension benefits, 401(k) Plan benefits, stock benefits or any other employee benefits,
or any other rights arising under federal, state or local laws prohibiting discrimination and/or harassment on the basis of race,
color, age, religion, sexual orientation, religious creed, sex, national origin, ancestry, alienage, citizenship, nationality,
mental or physical disability, denial of family and medical care leave, medical condition (including cancer and genetic characteristics),
marital status, military status, gender identity, harassment or any other basis prohibited by law. Notwithstanding the foregoing,
this release of claims against individual employees and stockholders is limited to claims based upon my employment with the Company.

 

    A-1

     

    

 

As a condition of the
Company entering into this Release, I further represent that I have not filed against the Company or any of the other Releasees,
any complaints, claims or lawsuits with any arbitral tribunal, administrative agency, or court prior to the date hereof, and that
I have not transferred to any other person any such complaints, claims or lawsuits. I understand that by signing this Release,
I waive my right to any monetary recovery in connection with a local, state or federal governmental agency proceeding and I waive
my right to file a claim seeking monetary damages in any arbitral tribunal, administrative agency, or court. This Release does
not: (i) prohibit or restrict me from communicating, providing relevant information to or otherwise cooperating with the U.S. Equal
Employment Opportunity Commission or any other governmental authority with responsibility for the administration of fair employment
practices laws regarding a possible violation of such laws or responding to any inquiry from such authority, including an inquiry
about the existence of this Release or its underlying facts, or (ii) require me to notify the Company of such communications or
inquiry. Furthermore, notwithstanding the foregoing, this Release does not include and will not preclude: (a) rights or claims
to vested benefits under any applicable retirement and/or pension plans; (b) rights under the Consolidated Omnibus Budget Reconciliation
Act of 1985 (“COBRA”); (c) claims for unemployment compensation; (d) rights to defense and indemnification,
if any, from the Company for actions or inactions taken by me in the course and scope of my employment with the Company and its
parents, subsidiaries and/or affiliates; (e) any rights I may have to obtain contribution as permitted by law in the event of entry
of judgment against the Company as a result of any act or failure to act for which I and the Company are held jointly liable; (f)
the right to any equity awards that vested prior to or because of the termination of my employment, and/or (g) any actions to enforce
the Agreement.

 

Nothing herein shall
be construed to limit my right to (1) respond accurately and fully to any question, inquiry or request for information when required
by legal process; or (2) disclose information to regulatory bodies. I understand that I am not required to contact the Company
before engaging in such communications.

 

I acknowledge that,
in signing this Release, I have not relied on any promises or representations, express or implied, other than those that are set
forth expressly herein or in the Agreement and that are intended to survive separation from employment, in accordance with the
terms of the Agreement.

 

I further acknowledge that:

 

	 	1.	I first received this Release on the date of the Agreement to which it is attached as Exhibit A;

 

	 	2.	I understand that, in order for this Release to be effective, I may not sign it prior to the date of my separation of employment with the Company but that if I wish to receive the Separation Benefits, I must sign and return this Release within 45 days of its presentation to me after my Termination of Employment;

 

	 	3.	I have carefully read and understand this Release;

 

	 	4.	The Company advised me to consult with an attorney and/or any other advisors of my choice before signing this Release;

 

	 	5.	I understand that this Release is LEGALLY BINDING and by signing it I give up certain rights;

 

    A-2

     

    

 

	 	6.	I have voluntarily chosen to enter into this Release and have not been forced or pressured in any way to sign it;

 

	 	7.	I acknowledge and agree that the Separation Benefits are contingent on execution of this Release, which releases all of my claims against the Company and the Releasees, and I KNOWINGLY AND VOLUNTARILY AGREE TO RELEASE the Company and the Releasees from any and all claims I may have, known or unknown, in exchange for the benefits I have obtained by signing, and that these benefits are in addition to any benefit I would have otherwise received if I did not sign this Release;

 

	 	8.	I have seven (7) days after I sign this Release to revoke it by notifying the Company in writing. The Release will not become effective or enforceable until the seven (7) day revocation period has expired;

 

	 	9.	This Release includes a WAIVER OF ALL RIGHTS AND CLAIMS I may have under the Age Discrimination in Employment Act of 1967 (29 U.S.C. §621 et seq.); and

 

	 	10.	This Release does not waive any rights or claims that may arise after this Release becomes effective, which is seven (7) days after I sign it, provided that I do not exercise my right to revoke this Agreement.

 

Intending to be legally bound, I have signed this Release as
of the date written below.

 

	Signature: __________________________	Date Signed: _____________

 

 

A-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]